Retro-inverso analogs of spadin display increased antidepressant effects
AssigneesMedincell, Centre National De La Recherche Scientifique
InventorsGeorges Gaudriault, Catherine Heurteaux, Jean Mazella, Marc Borsotto, Hamid Moha Ou Maati, Julie Veyssiere
Life of this patent
Estimating the term…
Abstract
Compositions, pharmaceutical compositions and biodegradable pharmaceutical compositions containing at least one analog of spadin or at least one analog of a propeptides of spadin or mixtures thereof are described. Methods for treating depression using the analogs of spadin or analogs of propeptides of spadin or mixtures thereof, as well as methods for blocking TREK-1 channel activity are also disclosed.
Claims5
A composition comprising at least one analog of spadin or at least one analog of a propeptide of spadin or mixtures thereof of said at least one analog, wherein said at least one analog is a retro-inverso peptide and is end-capped, and is selected from the group of:
- Ac-rlGwsvGipGswrplpa-NH2 (SEQ ID NO:4), Ac-rlGwsvGi-NH2 (SEQ ID NO:7), Ac-rlGwsvGipGswrplpaappppadlrdq-NH2 (SEQ ID NO:9), Ac-rlGwsvGipGswrplpaappppa-NH2 (SEQ ID NO:11), Ac-rrwrGGrpfaGGaaaarlGwsvGipGswrplpaappppadlrdq-NH2 (SEQ ID NO:13), Ac-rlawsvaipaswrplpa-NH2 (SEQ ID NO:
- 15), c(rlGwsvGipGswrplpa) (SEQ ID NO:20), c(rlGwsvGipGswrplparlGwsvGipGswrplpa) (SEQ ID NO:21) and mixtures thereof.
A pharmaceutical composition comprising, in a pharmaceutically acceptable vehicle, at least one analog of spadin or at least one analog of a propeptide of spadin or mixtures thereof of said at least one analog, wherein said at least one analog is a retro-inverso peptide and is end-capped, and is selected from the group of:
- Ac-rlGwsvGipGswrplpa-NH2 (SEQ ID NO:4), Ac-rlGwsvGi-NH2 (SEQ ID NO:7), Ac-rlGwsvGipGswrplpaappppadlrdq-NH2 (SEQ ID NO:9), Ac-rlGwsvGipGswrplpaappppa-NH2 (SEQ ID NO:11), Ac-rrwrGGrpfaGGaaaarlGwsvGipGswrplpaappppadlrdq-NH2 (SEQ ID NO:13), Ac-rlawsvaipaswrplpa-NH2 (SEQ ID NO:
- 15), c(rlGwsvGipGswrplpa) (SEQ ID NO:20), c(rlGwsvGipGswrplparlGwsvGipGswrplpa) (SEQ ID NO:21) and mixtures thereof.
A biodegradable pharmaceutical composition comprising at least one analog of spadin or at least one an analog of a propeptide of spadin or mixtures thereof of said at least one analog in a biodegradable slow release vehicle,
- wherein the at least one analog of spadin or the at least one analog of a propeptide of spadin or mixtures thereof of said at least one analog is a retro-inverso peptide and is end-caped, and is selected from the group of:
- Ac-rlGwsvGipGswrplpa-NH2 (SEQ ID NO:4), Ac-rlGwsvGi-NH2 (SEQ ID NO:7), Ac-rlGwsvGipGswrplpaappppadlrdq-NH2 (SEQ ID NO:9), Ac-rlGwsvGipGswrplpaappppa-NH2 (SEQ ID NO:11), Ac-rrwrGGrpfaGGaaaarlGwsvGipGswrplpaappppadlrdq-NH2 (SEQ ID NO:13), Ac-rlawsvaipaswrplpa-NH2 (SEQ ID NO:
- 15), c(rlGwsvGipGswrplpa) (SEQ ID NO:20), c(rlGwsvGipGswrplparlGwsvGipGswrplpa) (SEQ ID NO:21) and mixtures thereof.
A biodegradable pharmaceutical composition comprising Ac-rlGwsvGipGswrplpa-NH2 (SEQ ID NO:4) or Ac-rlGwsvGipGswrplpaappppadlrdq-NH2 (SEQ ID NO:9) or Ac-rlGwsvGipGswrplpa-NH2 (SEQ ID NO:4) and Ac-rlGwsvGipGswrplpaappppadlrdq-NH2 (SEQ ID NO:9) in a biodegradable slow release vehicle.
Dependencies are inferred from the claim text.